French drug maker Sanofi S.A. has agreed to make Moderna Inc.’s COVID-19 vaccine at its site in Ridgefield, New Jersey, and will fill and finish up to 200 million doses starting in September. Chief Executive Paul Hudson said the company will also continue to work on its two COVID1-19 vaccine programs, while supporting the global effort. The move is Sanofi’s third commitment to providing manufacturing support, and comes after it said it would make 125 million doses of the vaccine developed by BioNTech SE and Pfizer Inc. for the European Union. In February, Sanofi said it would support Johnson & Johnson by making about 12 million doses of that one-shot vaccine a month at a site in France. Sanofi is working with GlaxoSmithKline PLC to develop a COVID vaccine using the same recombinant protein-based manufacturing technology as one of its flu vaccines, combined with GSK’s established pandemic adjuvant platform. Separately, it is working with Translate Bio to develop an mRNA vaccine.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.